T Leist
Overview
Explore the profile of T Leist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, et al.
Mult Scler Relat Disord
. 2020 Dec;
46:102572.
PMID: 33296971
Background: Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10 mg (MAVENCLAD®; 3.5 mg/kg cumulative dose over 2 years,...
2.
Cohen B, Coyle P, Leist T, Oleen-Burkey M, Schwartz M, Zwibel H
Mult Scler Relat Disord
. 2015 Mar;
4(1):75-82.
PMID: 25787057
Objectives: The objective of the Therapy Optimization in MS (TOP MS) Study was to prospectively assess the relationship between MS disease-modifying therapy (DMT) adherence and MS relapse risk over 2...
3.
Butzkueven H, Chapman J, Cristiano E, GrandMaison F, Hoffmann M, Izquierdo G, et al.
Mult Scler
. 2007 Feb;
12(6):769-74.
PMID: 17263005
Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized in local and regional outcome studies in multiple sclerosis...
4.
Frank J, Richert N, Lewis B, Bash C, Howard T, Civil R, et al.
Mult Scler
. 2002 Apr;
8(1):24-9.
PMID: 11936485
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease...
5.
Spitsin S, Hooper D, Leist T, Streletz L, Mikheeva T, Koprowskil H
Mult Scler
. 2001 Nov;
7(5):313-9.
PMID: 11724447
Peroxynitrite has been implicated in the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Previously, we have shown that administration of uric acid (UA), a...
6.
Muraro P, Leist T, Bielekova B, McFarland H
J Neuroimmunol
. 2000 Nov;
111(1-2):186-94.
PMID: 11063837
Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-beta (IFN-beta) in multiple sclerosis (MS). We have serially monitored the cell surface expression of...
7.
Azimi N, Jacobson S, Leist T, Waldmann T
J Immunol
. 1999 Sep;
163(7):4064-72.
PMID: 10491011
Human T lymphotropic virus type I (HTLV-I) is the causative agent of an inflammatory neurological disease termed HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). An ongoing lymphocyte activation exists in patients with...
8.
Leist T, Althage A, Haenseler E, Hengartner H, Zinkernagel R
J Exp Med
. 1989 Jul;
170(1):269-77.
PMID: 2746160
The influence of major transplantation antigens on susceptibility to T cell-mediated disease caused by infection with the noncytopathic virus lymphocytic choriomeningitis virus (LCMV) was evaluated in B10 H-2-congenic mice. Susceptibility...
9.
Zinkernagel R, Pircher H, Schulz M, Leist T, Oehen S, Hengartner H
Cold Spring Harb Symp Quant Biol
. 1989 Jan;
54 Pt 2:843-51.
PMID: 2701218
No abstract available.
10.
Zinkernagel R, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A
J Exp Med
. 1986 Oct;
164(4):1075-92.
PMID: 3489805
A model for immunologically T cell-mediated hepatitis was established in mice infected with lymphocytic choriomeningitis virus (LCMV). The severity of hepatitis was monitored histologically and by determination of changes in...